<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03123445</url>
  </required_header>
  <id_info>
    <org_study_id>CLOG1701</org_study_id>
    <nct_id>NCT03123445</nct_id>
  </id_info>
  <brief_title>Endostar First-line Treatment of Advanced NSCLC</brief_title>
  <official_title>The Efficacy and Safety of Continuous Administration of Endostar Combined With Chemotherapy for Patients With Advanced no Small Cell Lung Cancer: An Open-label, no Randomized Controlled Multicenter Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaoning Tumor Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital of Shenyang Military Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Medical University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Explore the efficacy and safety of the treatment of Endostar continuous intravenous injection
      pump combined GP（gemcitabine+cisplatin） scheme for first-line advanced non small cell lung
      cancer and maintenance treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Explore the efficacy and safety of the treatment of Endostar continuous intravenous injection
      pump combined GP（gemcitabine+cisplatin） scheme for first-line advanced non small cell lung
      cancer and maintenance treatment.

      main objectives: PFS (progression-free survival) the secondary goal: ORR (overall response
      rate), DCR (disease control rate) and OS（overall survival）
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Time Frame: up to month 36</time_frame>
    <description>PFS is a tumor progression or death time of a patient who has an objective record on the date of enrollment. PFS calculation end if the patient was lost, unknown death , or other anti tumor therapy was used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>Time Frame: change from Baseline at the week 6, 12 of the treatment phase, the month 3, 6, 9 and 12, 15, 18, 21, 24, 27, 30 ,33,36 of the followup phase.</time_frame>
    <description>overall remission rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Endostar + Gemcitabine and Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will be given endostar combined with gemcitabine and cisplatine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine and Cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will be given gemcitabine and cisplatine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endostar</intervention_name>
    <description>Endostar,30mg continuous intravenous injection pump, d1-d7,21 days as one cycle, 4 cycles in total</description>
    <arm_group_label>Endostar + Gemcitabine and Cisplatin</arm_group_label>
    <other_name>Recombinant Human Endostatin Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine,1000mg/m2, i.v, d1 and d8 in each cycle, 21 days as one cycle, 4 cycles in total</description>
    <arm_group_label>Endostar + Gemcitabine and Cisplatin</arm_group_label>
    <arm_group_label>Gemcitabine and Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin,75mg/m2, i.v, d1 in each cycle, 21 days as one cycle, 4 cycles in total</description>
    <arm_group_label>Endostar + Gemcitabine and Cisplatin</arm_group_label>
    <arm_group_label>Gemcitabine and Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cytological and histological confirmation（Do not accept single sputum cytology in the
             diagnosis of patients） in patients diagnosed of lung squamous carcinoma; According to
             a new IASLC (International Association for the Study of Lung Cance) 2009 lung cancer
             TNM (tumor node metastasis) stages judged stage IIIB or IV non-small cell lung cancer.

          -  Must have at least one evaluated lesion,according to the RECIST version 1.1 standard
             (the longest diameter on spiral CT at least 10 mm,the longest diameter on plain CT at
             least 20 mm);

          -  Male or female, age between 18 and 75 years old ;

          -  ECOG(Eastern Cooperative Oncology Group) PS (performance status ) 0~1；

          -  Expected survival period ≥ 3 months or more

          -  Enough blood function: absolute neutrophil count (ANC)≥2 x 109 / L and the platelet
             count≥ 100 x 109 / L and hemoglobin ≥9 g/dL;

          -  Enough liver function: total bilirubin acuities≤the upper limit of normal (ULN);
             aspartate aminotransferase(AST) and Alanine aminotransferase(ALT) acuities ≤2.5 times
             of the upper limit of normal (ULN); Alkaline phosphatase ≤5 times of the upper limit
             of normal(ULN);

          -  Enough renal function：serum creatinine ≤the limit of normal(ULN) or calculated
             creatinine clearance≥60 mL/min.

          -  The electrocardiogram (ecg) basically normal,the body had no to heal wounds

          -  No previous anti-tumor drug therapy, or only received for non metastatic tumor of
             adjuvant or neoadjuvant chemotherapy, but has ended more than six months before the
             study start.

          -  Patients had surgery before,but have more than 4 weeks before the study start, and the
             patient has recovered;

          -  Women with completed uterus before intact in the group within 28 days must have a
             negative pregnancy test results (unless amenorrhea for 24 months). If the pregnancy
             test from the first time for more than 7 days,the patients need for urine pregnancy
             test(within 7 days before the first delivery).

          -  Prior to biological agents, especially e. coli genetically engineered products without
             severe allergic reactions;

          -  Sign the informed consent.

        Exclusion Criteria:

          -  Pregnancy, nursing mothers, or female patients with fertility but no contraception.

          -  Existing serious acute infection, and can not be controlled; Or with fester sex and
             chronic infection,or wound in delay;

          -  Original serious heart disease, including: congestive heart failure, uncontrolled high
             risk arrhythmia, unstable angina, myocardial infarction, severe valvular heart
             disease, and resistant hypertension;

          -  With uncontrolled nerve, mental illness or mental disorders, compliance is poor, can't
             cooperate and response to treatment; Uncontrolled primary brain tumors or central
             nervous system(CNS) metastases illness, with obvious symptoms in cranial hypertension
             or nerve spirit;

          -  With a bleeding tendency

          -  Researchers believe that patients should not participate in this test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>liu yunpeng, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Hospital of China Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>liu yunpeng, PhD</last_name>
    <phone>00862483282312</phone>
    <email>cmu_trial@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>jin bo, PhD</last_name>
    <phone>00862483282542</phone>
    <email>jb_cmu@126.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Wang J, Gu LJ, Fu CX, Cao Z, Chen QY. Endostar combined with chemotherapy compared with chemotherapy alone in the treatment of nonsmall lung carcinoma: A meta-analysis based on Chinese patients. Indian J Cancer. 2014 Mar;51 Suppl 3:e106-9. doi: 10.4103/0019-509X.154099.</citation>
    <PMID>25818734</PMID>
  </reference>
  <reference>
    <citation>Hu W, Fang J, Nie J, Dai L, Zhang J, Chen X, Ma X, Tian G, Wu D, Han S, Han J, Wang Y, Long J. Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer. Medicine (Baltimore). 2016 Jul;95(28):e4183. doi: 10.1097/MD.0000000000004183.</citation>
    <PMID>27428214</PMID>
  </reference>
  <reference>
    <citation>Rong B, Yang S, Li W, Zhang W, Ming Z. Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer. World J Surg Oncol. 2012 Aug 24;10:170. doi: 10.1186/1477-7819-10-170. Review.</citation>
    <PMID>22917490</PMID>
  </reference>
  <results_reference>
    <citation>Zhang FL, Gao EY, Shu RB, Wang H, Zhang Y, Sun P, Li M, Tang W, Jiang BQ, Chen SQ, Cui FB. Human Recombinant Endostatin Combined with Cisplatin Based Doublets in Treating Patients with Advanced NSCLC and Evaluation by CT Perfusion Imaging. Asian Pac J Cancer Prev. 2015;16(15):6765-8.</citation>
    <PMID>26434908</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2017</study_first_submitted>
  <study_first_submitted_qc>April 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Medical University, China</investigator_affiliation>
    <investigator_full_name>Yunpeng Liu</investigator_full_name>
    <investigator_title>Director of Department of Medical Oncology,The First Hospital of China Medical University Affiliation: China Medical University, China</investigator_title>
  </responsible_party>
  <keyword>endostar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Endostatins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

